Gritstone Bio Price to Sales Ratio 2017-2024 | GRTSQ
Historical PS ratio values for Gritstone Bio (GRTSQ) over the last 10 years. The current P/S ratio for Gritstone Bio as of October 22, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Gritstone Bio P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
|
0.00 |
|
nan |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.000B |
$0.016B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
